NCT06208683View on ClinicalTrials.gov

The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 4, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

December 1, 2024

Conditions
MumpsInfluenza
Interventions
BIOLOGICAL

Mumps vaccine, Live (MV)

0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus

BIOLOGICAL

Influenza Vaccine, inactivated, quadrivlent(QIV)

0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.

Trial Locations (3)

712099

Qindu Distric Center for Disease Prevention and Control, Xianyang

713199

Xingping Center for Disease Prevention and Control, Xianyang

719054

Yuyang Distict Center for Disease Prevention and Control, Yulin

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT06208683 - The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students | Biotech Hunter | Biotech Hunter